GLP-1 medicines like Wegovy, Ozempic, Zepbound, and Mounjaro are not started at their full dose. Every FDA label builds in a multi-week escalation ladder, and the reason is tolerability: raising the dose too fast is the main driver of nausea, vomiting, and other gastrointestinal side effects. This tool turns those label ladders into a dated calendar so you can plan refills, travel, and dose changes around a schedule your prescriber sets.
What the labels actually require
Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) both call for at least four weeks at each dose before moving up. Wegovy climbs 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg, reaching maintenance at 16 weeks. Tirzepatide climbs in 2.5 mg increments to a maximum of 15 mg. The low first dose — 0.25 mg or 2.5 mg — is an initiation dose to let your body adjust; it is not expected to drive weight loss on its own. Some telehealth services advertise faster ramps, but the labels do not support escalating before four weeks at a dose.
Staying longer at a dose is allowed
If a dose is hard to tolerate, the labels support staying on it longer rather than pushing ahead — and 1.7 mg is an accepted Wegovy maintenance dose if 2.4 mg is not tolerated. The Slow and Very slow pace options model exactly this: +2 or +4 weeks at every step. Delaying escalation is generally preferable to stopping the medication, but only your prescriber can decide the right dose and timing for you.
Planning refills, travel, and missed doses
Because injections are weekly, a titration calendar makes it easy to line up refills and pack the right pens for a trip. If you miss a dose, the rules differ by molecule: semaglutide can be taken within 5 days of the missed dose, tirzepatide within 4 days (96 hours) — otherwise skip it and resume your normal schedule, never doubling up. You can also change your injection day as long as you keep at least 48 hours (semaglutide) or 72 hours (tirzepatide) between doses; the calculator shifts your schedule forward to respect that minimum gap.